Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350517 | 0.88 | PNMT (0.39) | PNMTTAAR1LOXL2DPP4KDM1A | |
| SCHEMBL1765257 | 0.88 | PNMT (0.39) | PNMTTAAR1LOXL2DPP4KDM1A | |
| SCHEMBL27807410 | 0.82 | PNMT (0.35) | PNMTTAAR1LOXL2DPP4 | |
| SCHEMBL31593875 | 0.82 | CD44 (0.41) | PNMTTAAR1LOXL2DPP4 | |
| SCHEMBL13527770 | 0.81 | LOXL2 (0.42) | TAAR1LOXL2DPP4MEN1MAPT | |
| SCHEMBL1764780 | 0.80 | PNMT (0.41) | PNMTTAAR1LOXL2DPP4KDM1A | |
| SCHEMBL27717591 | 0.79 | PNMT (0.33) | PNMTTAAR1MAPT | |
| SCHEMBL620594 | 0.76 | DPP4 (0.46) | TAAR1LOXL2DPP4MEN1MAPT | |
| SCHEMBL626553 | 0.75 | PNMT (0.50) | PNMTTAAR1DPP4 | |
| SCHEMBL31618915 | 0.75 | RAB9A (0.35) | TAAR1MEN1MAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | PNMT 2492/4885TAAR1 83/4885LOXL2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.